ST光一(300356.SZ):實控人龍昌明被司法拍賣的360萬股 由南京千創科技拍得
格隆匯12月16日丨ST光一(300356.SZ)公佈,公司實際控制人龍昌明持有的公司部分股份360萬無限售流通股被深圳市福田區人民法院於2021年12月2日10時至2021年12月3日10時止,在淘寶網司法拍賣平台上進行司法拍賣。
根據淘寶網司法拍賣網絡平台發佈的《網絡競價成功確認書》,具體內容如下:
用户姓名南京千創科技有限責任公司通過競買號B6035於2021年12月3日在深圳市福田區人民法院於阿里拍賣平台開展的“龍昌明持有的“ST光一”(證券代碼:300356)股票360萬股”項目公開競價中,以最高應價勝出。該標的網絡拍賣成交價格1227.68萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.